Navigation Links
VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting
Date:4/20/2009

FMT(TM) Quantitative Tomographic Imaging Being Expanded to Four Fluorescent Channels to Enable Greater Data Ranges and Multiplexing of Disease Biomarkers In Vivo

VisEn Multi-Modality Imaging Adapter Series Launched to Enable Imaging, Co-Registration and Data Fusion Between FMT and CT, MR, Spect and PET

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced that users of its FMT 2500 Quantitative Tomography Platform will soon be able to access four channels of quantitative fluorescent imaging -- 635 nm, 670 nm, 745 nm, and 790 nm -- allowing greater flexibility in imaging and multiplexing of VisEn's fluorescent imaging agents in multiple disease pathways in vivo. VisEn also announced today that it has launched its proprietary line of FMT Multi-Modality Adaptors designed to enable researchers to readily combine FMT readouts with imaging results from complementary microCT, PET, MR and Spect platforms. The announcements were made during the AACR (American Association of Cancer Research) 100th Annual Meeting 2009, being held April 18-22, 2009 in Denver, CO.

FMT 2500 Four Channel Imaging Upgrade and System Available Summer 2009

The expanded FMT 2500 Four Channel offering will become available in the summer of 2009 and can be purchased as an upgrade to existing FMT 2500 systems, or as an added feature to a new FMT system. In addition to the standard wavelengths of 670 nm and 745 nm offered in the FMT 2500, VisEn will now offer customers FMT imaging in two new laser wavelengths: 635 nm and 790 nm. Upgrading the FMT 2500 from two to four channels to span a broader spectral fluorescence range from 650 - 850 nm allows researchers greater imaging and fluorescence quantification capability in vivo.

"This expanded range of multi-modality and
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. OBS Medicals Visensia Patient Monitoring Technology Lowers Cost of Medical Malpractice Insurance
2. CRi to Distribute VisEn Medicals Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America
3. VisEn Co-Founder Named Radiologic Societys Outstanding Researcher of the Year
4. VisEn Medical Raises $5.0 Million in Expanded Series B Financing
5. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
6. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
7. Spring Lineup of Medical Spa Webinars for MedSpa Professionals by Acara
8. Matrixmj.Com Revolutionizing The Way Medical Professionals Seek And Find Employment; Job Board Debuts Innovative Method For Matching Healthcare Candidates And Job Opportunties
9. reThinking eHealth Webinar: Will the Patient Centered Medical Home Be the Model for Universal Healthcare?
10. Medical EMR Software To Be Subdized In Pres. Obama's Economic Stimulus Plan - Lives Can Be Saved As A Result
11. Veteran Medical Malpractice Litigator Gary S. Genovese Re-Joins Conrad & Scherer LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ... from the pivotal Phase 2b 003-A1 study, known ... well-tolerated in heavily pre-treated relapsed and refractory multiple ... the ASH/ASCO Joint Symposium at the 51st annual ... in New Orleans. Enrollment in this trial is ...
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/6/2009)... says dangerous substances such as asbestos have been found in toys ... ... (PRWEB) December 6, 2009 -- As parents shop for children,s toys ... recalls due to lead paint or asbestos contamination, says a New ... emergency rooms each year due to toy-related injuries,” says Joseph W. ...
(Date:12/5/2009)... What: Cuts for a Cause ,, Why: ... and other terminal illnesses affecting children. All proceeds from each ... Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... in Falls Church for all guests. Hoa Lai, a DJ ...
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative ... Research presented today at the 51st Annual Meeting ... new treatment options and improved diagnostic methods for ... leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... Physicians with Flexibility and Control for Lead ... ... SPNC ) today announced the availability of the new LLD,EZ Lead ... leads. The LLD EZ enables physicians to secure,the entire lead creating traction ...
... WELLINGTON, Fla., May 15 The Quantum Group,Inc. ... announced today,through its subsidiary, Renaissance Health Systems, Inc. ... to centralize information pertaining,to the top five (5) ... and secure,HIPAA compliant environment. In addition to providing ...
... grant program will fund a pilot study in Vietnam ... for getting type 2 diabetes and promote a program ... , The National Hospital of Endocrinology (NHOE) will launch ... questionnaires (1) , the investigators hope to identify people ...
... Inc., the developer,of the first and only flexible ... surgery, today announced the closing of a $25 ... healthcare venture capital,and private equity firm, led the ... Stata Venture Partners, 3i, Argonaut,Ventures, ESI, Gainesborough Investments, ...
... Enables Creation of Global Unified Worklist ... or System, SEATTLE, May 15 Compressus, ... Seattle Radiologists, APC, of,Seattle, announced today an agreement ... imaging and data management systems.,The implementation, which will ...
... wealth of healthcare and medical device experience to board ... of ... developer,of the first and only flexible CO2 laser scalpel enabling new ... been,elected to the company,s board of directors. Suennen, co-founder and,managing member ...
Other Medicine News:Health News:Spectranetics Introduces New Device for Removal of Non-Functional and Infected Cardiac Leads 2Health News:Spectranetics Introduces New Device for Removal of Non-Functional and Infected Cardiac Leads 3Health News:The Quantum Group Announces Web-Based Portal for Physicians 2Health News:The Quantum Group Announces Web-Based Portal for Physicians 3Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration 2Health News:OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration 3Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2
(Date:12/4/2009)... (NYSE: WPI ), a leading global specialty ... Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with ... market its 8mg ramelteon tablets prior to the expiration ... Watson,s 8mg ramelteon tablet product is a generic ...
(Date:12/4/2009)... disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), ... comorbidities reported to occur more often in people ... versus those without an epilepsy diagnosis, according to ... U.S. ,, Findings from " CNS-Related Comorbidities in ...
(Date:12/3/2009)... (Nasdaq: PCYC ), a biopharmaceutical company focused on ... treatment of immune mediated diseases and cancer, today announced ... on, Tuesday, December 8, 2009 at 11:00am Eastern Time ... clinical data regarding its HDAC Program (PCI-24781) and its ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Young Ballerinas May Face Heart Bone Risks 47452 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3
... Jan. 7 ImQuest Life Sciences announced today the ... and Drug Administration to initiate human clinical trials for ... their Phase 1 studies in the first quarter of ... HIV which primarily acts as a nonnucleoside reverse transcriptase ...
... U.S., U.K. and China TrialsSAN DIEGO, Jan. 7 ... liver disease, today announced patient enrollment has begun for ... will study the Extracorporeal Liver Assist Device (ELAD) as ... under three protocols. The study is open for enrollment ...
Other Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: